AC Immune SA expected to post a loss of 17 rappen a share - Earnings Preview

• AC Immune SA ACIU is expected to show a rise in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

• The Lausanne Vaud-based company is expected to report a 188.2% increase in revenue to CHF1.98 million from CHF687 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for AC Immune SA is for a loss of 17 rappen per share.

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for AC Immune SA is $9.00, about 76% above its last closing price of $2.16

Previous quarterly performance (using preferred earnings measure in Swiss francs). ​

This summary was machine generated August 1 at 13:20 GMT. All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)